Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Tofflon Science and Technology Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥14.39 |
52 Week High | CN¥27.57 |
52 Week Low | CN¥11.70 |
Beta | 0.60 |
1 Month Change | -8.40% |
3 Month Change | -19.43% |
1 Year Change | -46.59% |
3 Year Change | -32.60% |
5 Year Change | 31.54% |
Change since IPO | 28.89% |
Recent News & Updates
Shareholder Returns
300171 | CN Medical Equipment | CN Market | |
---|---|---|---|
7D | -10.9% | -4.1% | -2.2% |
1Y | -46.6% | -17.1% | -14.8% |
Return vs Industry: 300171 underperformed the CN Medical Equipment industry which returned -17.1% over the past year.
Return vs Market: 300171 underperformed the CN Market which returned -14.8% over the past year.
Price Volatility
300171 volatility | |
---|---|
300171 Average Weekly Movement | 6.3% |
Medical Equipment Industry Average Movement | 7.7% |
Market Average Movement | 8.1% |
10% most volatile stocks in CN Market | 11.4% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 300171's share price has been volatile over the past 3 months.
Volatility Over Time: 300171's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 5,239 | Xiaodong Zheng | https://www.tofflon.com |
Tofflon Science and Technology Group Co., Ltd. operates as a pharmaceutical equipment supplier for the pharma and biotech industries worldwide. It offers injectables, such as auto solution preparation systems, aseptic filling lines for ampoule, vials, syringes and powders, freeze dryer and auto loading systems, barrier systems, and plastic packaging machines.
Tofflon Science and Technology Group Co., Ltd. Fundamentals Summary
300171 fundamental statistics | |
---|---|
Market cap | CN¥10.95b |
Earnings (TTM) | CN¥825.51m |
Revenue (TTM) | CN¥5.98b |
13.3x
P/E Ratio1.8x
P/S RatioIs 300171 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300171 income statement (TTM) | |
---|---|
Revenue | CN¥5.98b |
Cost of Revenue | CN¥3.79b |
Gross Profit | CN¥2.19b |
Other Expenses | CN¥1.37b |
Earnings | CN¥825.51m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 1.09 |
Gross Margin | 36.67% |
Net Profit Margin | 13.81% |
Debt/Equity Ratio | 0% |
How did 300171 perform over the long term?
See historical performance and comparison